[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 2,336
Citations 0
News From the Food and Drug Administration
July 16, 2019

Episodic Cluster Headache Antibody Therapy

JAMA. 2019;322(3):199. doi:10.1001/jama.2019.9917

A monoclonal antibody that the FDA approved last year to prevent chronic and episodic migraine has now received approval to treat episodic cluster headache in adults. The drug blocks calcitonin gene-related peptide ligand—a potent vasodilator that modulates nociceptive trigeminal neurons involved in the pathophysiology of cluster headaches. Patients can self-inject galcanezumab, marketed as Emgality.